SCHEMBL366713

SCHEMBL366713

COc1cccc(COc2ccc(C(=O)NS(C)(=O)=O)cc2)c1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 3/20 0.57
SMN1; SMN2 Q16637 3/20 0.57
ALDH1A1 P00352 2/20 0.57
NPC1 O15118 2/20 0.57
LMNA P02545 2/20 0.57
KDM4E B2RXH2 1/20 0.57
MAOB P27338 2/20 0.54
MRGPRX4 Q96LA9 4/20 0.54
TP53 P04637 2/20 0.54
PKM P14618 1/20 0.54
NFKB1 P19838 1/20 0.54
NFKB2 Q00653 1/20 0.54
RELA Q04206 1/20 0.54
RXFP1 Q9HBX9 1/20 0.54
SPHK2 Q9NRA0 2/20 0.53
SPHK1 Q9NYA1 2/20 0.53
MEN1 O00255 1/20 0.53
HPGD P15428 1/20 0.53
KMT2A Q03164 1/20 0.53
NPSR1 Q6W5P4 1/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL364835 0.89 SMPD1 (0.60) ALDH1A1LMNAMAOBMRGPRX4SPHK2
SCHEMBL366467 0.86 MMP2 (0.60) MAOBMRGPRX4CYP4F2CYP4A11
SCHEMBL365645 0.86 ALDH1A1 (0.70) RAB9ASMN1; SMN2ALDH1A1NPC1LMNA
SCHEMBL16239768 0.86 ALDH1A1 (0.70) RAB9ASMN1; SMN2ALDH1A1NPC1LMNA
SCHEMBL365474 0.85 MAOB (0.67) MAOBMRGPRX4CYP4F2CYP4A11MMP13
SCHEMBL16239839 0.85 MAOB (0.67) RAB9ASMN1; SMN2ALDH1A1NPC1LMNA
SCHEMBL365173 0.84 MAOB (0.61) RAB9ASMN1; SMN2ALDH1A1NPC1KDM4E
Diethylamine SCHEMBL14890330 0.84 SMPD1 (0.55) RAB9AALDH1A1NPC1LMNAMAOB
SCHEMBL363886 0.82 MAOB (0.69) MAOBMRGPRX4SPHK2SPHK1L3MBTL1
SCHEMBL3646136 0.82 RAB9A (0.65) RAB9ASMN1; SMN2ALDH1A1NPC1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9096500-B2 Acyl sulfonamide compounds PFIZER LIMITED (GB) 2015-08-04 US disclosed
EP-2593428-B1 N-SULFONYLBENZAMIDES AS INHIBITORS OF VOLTAGE-GATED SODIUM CHANNELS PFIZER LTD (GB) 2014-11-19 EP disclosed
EP-2593428-A2 N-SULFONYLBENZAMIDES AS INHIBITORS OF VOLTAGE-GATED SODIUM CHANNELS Pfizer Limited (GB) 2013-05-22 EP disclosed
US-20130109701-A1 Chemical Compounds PFIZER LIMITED (GB) 2013-05-02 US disclosed
WO-2012007868-A2 CHEMICAL COMPOUNDS PFIZER LIMITED (GB) 2012-01-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130109701-A1 Chemical Compounds SCN1A, SCN1B, SCN7A RAB9A 987/4885SMN1; SMN2 236/4885ALDH1A1 767/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.